168 related articles for article (PubMed ID: 17520872)
41. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis.
Manguso F; Balzano A
Aliment Pharmacol Ther; 2007 Jul; 26(1):21-9. PubMed ID: 17555418
[TBL] [Abstract][Full Text] [Related]
42. Management of acute severe ulcerative colitis.
Doherty GA; Cheifetz AS
Expert Rev Gastroenterol Hepatol; 2009 Aug; 3(4):395-405. PubMed ID: 19673626
[TBL] [Abstract][Full Text] [Related]
43. Annular purpura and ulcerative colitis: response to infliximab.
Tan V; Bartlett M; Hosking P; Gibson PR
Dig Liver Dis; 2007 May; 39(5):488-9. PubMed ID: 17383245
[No Abstract] [Full Text] [Related]
44. We once were blind and now we see: is it time to treat ulcerative colitis to achieve mucosal healing?
Rubin DT
Clin Gastroenterol Hepatol; 2011 Jun; 9(6):456-7. PubMed ID: 21421077
[No Abstract] [Full Text] [Related]
45. "Take your medicine": nonadherence issues in patients with ulcerative colitis.
Turnbough L; Wilson L
Gastroenterol Nurs; 2007; 30(3):212-7; quiz 218-9. PubMed ID: 17568260
[TBL] [Abstract][Full Text] [Related]
46. Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis.
Veerappan SG; Kennedy M; O'Morain CA; Ryan BM
Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):588-9. PubMed ID: 18467922
[No Abstract] [Full Text] [Related]
47. Tixocortol Pivalate (JO 1016).
Friedman G
Am J Gastroenterol; 1983 Aug; 78(8):529-30. PubMed ID: 6410909
[No Abstract] [Full Text] [Related]
48. Efficient Early Drug Development for Ulcerative Colitis.
Khanna R; Jairath V; Vande Casteele N; Mosli MH; Zou G; Parker CE; Levesque BG; Sandborn WJ; D'Haens G; Feagan BG
Gastroenterology; 2016 May; 150(5):1056-1060. PubMed ID: 27018491
[No Abstract] [Full Text] [Related]
49. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
Hellström PM; Schmidt D; Karlén P
Lakartidningen; 2007 Oct 10-16; 104(41):2973-6. PubMed ID: 17977308
[No Abstract] [Full Text] [Related]
50. Budesonide for ulcerative colitis.
Marín-Jiménez I; Peña AS
Rev Esp Enferm Dig; 2006 May; 98(5):362-73. PubMed ID: 16944997
[TBL] [Abstract][Full Text] [Related]
51. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
[TBL] [Abstract][Full Text] [Related]
52. [Observation on curative effect of chronic ulcerative colitis treated by retention enema with combination of Chinese and Western drugs].
Wang XY; Wu Y; Jiang XM
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Dec; 27(12):1123-5. PubMed ID: 18198649
[TBL] [Abstract][Full Text] [Related]
53. [Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis].
Mocciaro F; Orlando A; Scimeca D; Cottone M
Recenti Prog Med; 2007 Nov; 98(11):560-4. PubMed ID: 18044405
[TBL] [Abstract][Full Text] [Related]
54. Fatal myocardial infarction in an elderly woman with severe ulcerative colitis: what is the role of steroids?
Baty V; Blain H; Saadi L; Jeandel C; Canton Ph
Am J Gastroenterol; 1998 Oct; 93(10):2000-1. PubMed ID: 9772083
[No Abstract] [Full Text] [Related]
55. [Posterior subcapsular cataract in a case of ulcerative colitis treated with corticosteroid enema].
Patteau F; Bourcier T; Naacke H; Allahdadi H; Borderie V; Laroche L
J Fr Ophtalmol; 2003 Oct; 26(8):834-6. PubMed ID: 14586226
[TBL] [Abstract][Full Text] [Related]
56. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
[TBL] [Abstract][Full Text] [Related]
57. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
Sandborn WJ
J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908
[TBL] [Abstract][Full Text] [Related]
58. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
Safdi AV; Cohen RD
Aliment Pharmacol Ther; 2007 Nov; 26(9):1179-86. PubMed ID: 17944732
[TBL] [Abstract][Full Text] [Related]
59. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
Tsai HH; Punekar YS; Morris J; Fortun P
Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
[TBL] [Abstract][Full Text] [Related]
60. Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis.
Mollinedo F; Gajate C; Morales AI; del Canto-Jañez E; Justies N; Collía F; Rivas JV; Modolell M; Iglesias A
J Pharmacol Exp Ther; 2009 May; 329(2):439-49. PubMed ID: 19244550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
